SEARCH

SEARCH BY CITATION

References

  • 1
    Vachvanichsanong P, Dissaneewate P, McNeil E. Twenty-two years’ experience with childhood-onset SLE in a developing country: are outcomes similar to developed countries? Arch Dis Child. 2011;96:4449.
  • 2
    eHealthMe: real world drug outcomes. Available at: http://www.ehealthme.com/ds/cyclophosphamide/hypertensive+encephalopathy. December 16, 2011.
  • 3
    Austin HA 3rd, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314:614619.
  • 4
    Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64:620625.
  • 5
    Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:22192228.
  • 6
    Jones BV, Egelhoff JC, Patterson RJ. Hypertensive encephalopathy in children. AJNR Am J Neuroradiol. 1997;18:101106.
  • 7
    Hu MH, Wang HS, Lin KL, et al. Clinical experience of childhood hypertensive encephalopathy over an eight year period. Chang Gung Med J. 2008;31:153158.
  • 8
    New DI, Chesser AM, Thuraisingham RC, et al. Cerebral artery responses to pressure and flow in uremic hypertensive and spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2003;284:H1212H1216.
  • 9
    Cellucci T, Benseler SM. Posterior reversible encephalopathy syndrome: increasing recognition of an important clinical entity in young patients with systemic lupus erythematosus. J Rheumatol. 2011;38:15441545.